Apr 2018 $1 M Private placement after listing Under $2 million 1
Onconova Therapeutics Inc.: Private sale, Apr 2018 × Investors in this round 1 investor had bought by the notice of Jun 8, 2018: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $1 M offered
Smallest investment taken $1,250,000
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Up to $1 million
Sales commissions $75,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice Manoj M. Maniar · Executive Officer Mark P. Guerin · Executive Officer Ramesh S. Kumar · Executive Officer, Director Steven M. Fruchtman · Executive Officer E. Premkumar J. Reddy · Director Henry S. Bienen · Director Jack E. Stover · Director James J. Marino · Director Jerome E. Groopman · Director Michael B. Hoffman · Director Viren S. Mehta · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Lucas Advisors LLC d/b/a KYBORA Emerging Markets · broker-dealer Lucas Advisors LLC d/b/a KYBORA Emerging Markets · Lambertville, New Jersey Sold in no state named, and outside the US Signed by Mark P. Guerin, Chief Financial Officer. Newest notice filed Jun 8, 2018. Read the notice at the SEC .
equity SEC Oct 2015 $2 M Private placement after listing Under $2 million 1
Onconova Therapeutics Inc.: Private sale, Oct 2015 × Investors in this round 1 investor had bought by the notice of Oct 23, 2015: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $17 M offered; $15 M still to sell
Smallest investment taken $1,500,000
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people $100,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Ajay M. Bansal · Executive Officer Manoj M. Maniar · Executive Officer Ramesh Kumar, Ph.D · Executive Officer, Director Steven M. Fruchtman · Executive Officer Thomas M. McKearn · Executive Officer Anne M. VanLent · Director E. Premkumar Reddy · Director Henry S Bienen · Director James M. Marino · Director Jerome E. Groopman · Director Michael M. Hoffman · Director Viren E. Mehta · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Proceeds may be used for general corporate purposes, which may include payment of executive salaries.”Signed by Ajay Bansal, Chief Financial Officer. Newest notice filed Oct 23, 2015. Read the notice at the SEC .
equity SEC Jul 2012 $50 M No. 4 $50 to $250 million 1
Onconova Therapeutics Inc.: Raise no. 4, Jul 2012 × Investors in this round 1 investor had bought by the notice of Aug 13, 2012: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $50 M of $50 M offered
Smallest investment taken $49,999,999
What was sold equity
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $2,000,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice E. Premkumar Reddy, Ph.D · Executive Officer, Director Ramesh Kumar, Ph.D · Executive Officer, Director Alan R. Williamson · Director Henry S. Bienen · Director K. R. Ravindra · Director Michael R. Hoffman · Director Pankaj R. Patel · Director Shekhar S. Kundur · Director Viren R. Mehta · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Aquilo Partners, L.P. (CRD 114909) · San Francisco, California Sold in IL Remarks in the notice On the use of proceeds: “Proceeds will be used for working capital and general corporate purposes.”Signed by Ramesh Kumar, Ph.D, President. Newest notice filed Aug 13, 2012. Read the notice at the SEC .
equity SEC Apr 2012 $26 M No. 3 $10 to $50 million 41
Onconova Therapeutics Inc.: Raise no. 3, Apr 2012 × Investors in this round 41 investors had bought by the notice of Jul 26, 2012: 41 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $26 M of $30 M offered; $4 M still to sell
Smallest investment taken $1,000
What was sold equity, options or other rights to buy securities, other: Convertible Promissory Notes, convertible into Series I Preferred Stock, under certain circumstances.
Meant to last a year or less
Issuer's revenue $5 million to $25 million
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice E. Premkumar Reddy, Ph.D. · Executive Officer, Director Ramesh Kumar, Ph.D. · Executive Officer, Director Alan R. Williamson · Director Henry S. Bienen · Director K. R. Ravindra · Director Michael R. Hoffman · Director Pankaj R. Patel · Director Viren R. Mehta · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Proceeds will be used for working capital and general corporate purposes.”Signed by Ramesh Kumar, Ph.D., President. Newest notice filed Jul 26, 2012 (1 amendment). Read the notice at the SEC .
equity, options SEC Sep 2010 $12 M No. 2 $10 to $50 million 67
Onconova Therapeutics Inc.: Raise no. 2, Sep 2010 × Investors in this round 67 investors had bought by the notice of Jan 5, 2011: 67 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $12 M of $20 M offered; $8 M still to sell
Smallest investment taken no minimum stated
What was sold equity
Meant to last a year or less
Issuer's revenue $1 million to $5 million
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice E. Premkumar Reddy, Ph.D. · Executive Officer, Director Ramesh Kumar, Ph.D. · Executive Officer, Director Alan R. Williamson · Director Henry B. Binen · Director K. R. Ravindra · Director Michael R. Hoffman · Director Pankaj R. Patel · Director Viren R. Mehta · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Proceeds will be used for working capital and general corporate purposes”Signed by Ramesh Kumar, Ph.D., President. Newest notice filed Jan 5, 2011 (1 amendment). Read the notice at the SEC .
equity SEC May 2009 $19 M No. 1 $10 to $50 million 58
Onconova Therapeutics Inc.: Raise no. 1, May 2009 × Investors in this round 58 investors had bought by the notice of Mar 4, 2010: 58 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $19 M of $26 M offered; $7 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue $1 million to $5 million
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice E. Premkumar Reddy, Ph.D. · Executive Officer, Director Ramesh Kumar, Ph.D. · Executive Officer, Director Alan R. Williamson · Director Henry S. Bienen, Ph.D. · Director K R. Ravindra · Director Michael B. Hoffman · Director Pankaj S. Patel · Director Viren R. Mehta · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “The total offering amount reflects the purchase price of the Series G Convertible Preferred Stock and warrants to purchase shares of Series G Convertible Preferred Stock, and the exercise price of the warrants.”On the use of proceeds: “Proceeds to be used for working capital and other general corporate purposes, which include salaries payable in the ordinary course of business.”Signed by Ramesh Kumar, Ph.D., President. Newest notice filed Mar 4, 2010 (1 amendment). Read the notice at the SEC .
equity, options SEC